TY - JOUR
T1 - Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis
AU - Nelson, John D.
AU - Shelton, Sharon
AU - Kusmiesz, Helen T.
AU - Haltalin, Kenneth C.
PY - 1972/1/1
Y1 - 1972/1/1
N2 - Thirty-seven infants and children with acute shigellosis were treated with orally administered ampicillin or nalidixic acid. Peak plasma levels and dose-response curves suggested two patient populations. Five of 16 patients receiving nalidixic acid had a pronounced delay in absorption, while the others had the anticipated peak levels and plasma half-lifes. All patients had a lower percentage of conjugated drug and of drug present as the hydroxynalidixic acid metabolite on the first day of treatment than during convalescence. Thus, some patients with diarrhea had altered absorption and all had altered metabolism of nalidixic acid during the acute phase of shigellosis. In 10 of 21 ampicillin-treated patients there were depressed plasma levels and prolonged half-lifes. These were statistically likely to be younger, to have more severe diarrhea, and to have lower body weight than those with normal peak plasma levels and plasma clearance rates.
AB - Thirty-seven infants and children with acute shigellosis were treated with orally administered ampicillin or nalidixic acid. Peak plasma levels and dose-response curves suggested two patient populations. Five of 16 patients receiving nalidixic acid had a pronounced delay in absorption, while the others had the anticipated peak levels and plasma half-lifes. All patients had a lower percentage of conjugated drug and of drug present as the hydroxynalidixic acid metabolite on the first day of treatment than during convalescence. Thus, some patients with diarrhea had altered absorption and all had altered metabolism of nalidixic acid during the acute phase of shigellosis. In 10 of 21 ampicillin-treated patients there were depressed plasma levels and prolonged half-lifes. These were statistically likely to be younger, to have more severe diarrhea, and to have lower body weight than those with normal peak plasma levels and plasma clearance rates.
UR - http://www.scopus.com/inward/record.url?scp=0015426664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0015426664&partnerID=8YFLogxK
U2 - 10.1002/cpt1972136879
DO - 10.1002/cpt1972136879
M3 - Article
C2 - 4673233
AN - SCOPUS:0015426664
SN - 0009-9236
VL - 13
SP - 879
EP - 886
JO - Clinical Pharmacology & Therapeutics
JF - Clinical Pharmacology & Therapeutics
IS - 6
ER -